Donepezil Hydrochloride; Memantine Hydrochloride is Used for managing moderate to severe dementia in Alzheimer's disease. It was first introduced by Abbvie Inc in its drug Namzaric on Dec 23, 2014. 5 different companies have introduced drugs containing Donepezil Hydrochloride; Memantine Hydrochloride.

Donepezil Hydrochloride; Memantine Hydrochloride Patents

Given below is the list of patents protecting Donepezil Hydrochloride; Memantine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Namzaric	US8058291	Methods and compositions for the treatment of CNS-related conditions	Dec 05, 2029	Abbvie
Namzaric	US8039009 (Pediatric)	Modified release formulations of memantine oral dosage forms	Sep 24, 2029	Abbvie
Namzaric	US8039009	Modified release formulations of memantine oral dosage forms	Mar 24, 2029	Abbvie
Namzaric	US8168209 (Pediatric)	Method and composition for administering an NMDA receptor antagonist to a subject	May 22, 2026	Abbvie
Namzaric	US8173708 (Pediatric)	Method and composition for administering an NMDA receptor antagonist to a subject	May 22, 2026	Abbvie
Namzaric	US8283379 (Pediatric)	Methods and compositions for the treatment of CNS-related conditions	May 22, 2026	Abbvie
Namzaric	US8329752 (Pediatric)	Composition for administering an NMDA receptor antagonist to a subject	May 22, 2026	Abbvie
Namzaric	US8362085 (Pediatric)	Method for administering an NMDA receptor antagonist to a subject	May 22, 2026	Abbvie
Namzaric	US8598233 (Pediatric)	Method for administering an NMDA receptor antagonist to a subject	May 22, 2026	Abbvie
Namzaric	US8168209	Method and composition for administering an NMDA receptor antagonist to a subject	Nov 22, 2025	Abbvie
Namzaric	US8173708	Method and composition for administering an NMDA receptor antagonist to a subject	Nov 22, 2025	Abbvie
Namzaric	US8283379	Methods and compositions for the treatment of CNS-related conditions	Nov 22, 2025	Abbvie
Namzaric	US8293794	Methods and compositions for the treatment of CNS-related conditions	Nov 22, 2025	Abbvie
Namzaric	US8329752	Composition for administering an NMDA receptor antagonist to a subject	Nov 22, 2025	Abbvie
Namzaric	US8338485	Compositions for the treatment of CNS-related conditions	Nov 22, 2025	Abbvie
Namzaric	US8338486	Methods for the treatment of CNS-related conditions	Nov 22, 2025	Abbvie
Namzaric	US8362085	Method for administering an NMDA receptor antagonist to a subject	Nov 22, 2025	Abbvie
Namzaric	US8580858	Compositions for the treatment of CNS-related conditions	Nov 22, 2025	Abbvie
Namzaric	US8598233	Method for administering an NMDA receptor antagonist to a subject	Nov 22, 2025	Abbvie
Namzaric	US5061703 (Pediatric)	Adamantane derivatives in the prevention and treatment of cerebral ischemia	Oct 11, 2015 (Expired)	Abbvie
Namzaric	US5061703	Adamantane derivatives in the prevention and treatment of cerebral ischemia	Apr 11, 2015 (Expired)	Abbvie

Add above patents to watchlist

Donepezil Hydrochloride; Memantine Hydrochloride's Family Patents

Full family tree

Donepezil Hydrochloride; Memantine Hydrochloride Generic API Manufacturers

Several generic applications have been filed for Donepezil Hydrochloride; Memantine Hydrochloride. The first generic version for Donepezil Hydrochloride; Memantine Hydrochloride was by Amneal Pharmaceuticals Llc and was approved on Jan 27, 2017. And the latest generic version is by Xiamen Lp Pharmacuetical Co Ltd and was approved on Jul 15, 2025.

Given below is the list of companies who have filed for Donepezil Hydrochloride; Memantine Hydrochloride generic, along with the locations of their manufacturing plants worldwide.